CD274 and neoplasm: NSCLC patients with a higher tumor tissue TMB (tTMB) are correlated with a more effective response to PD-1/PD-L1 inhibitors by leading to tumor-specific neoantigen formation to elevate tumor immunogenicity (31–34).